Ipsen (ENXTPA:IPN) has come into focus after presenting fresh preclinical data at the AACR (American Association for Cancer Research) congress for two first-in-class oncology candidates, IPN01203 and IPN60300, targeting difficult solid tumor indications.
First-in-Class Oncology Candidates
IPN01203 is an investigational, first-in-class T-cell activator designed to treat advanced solid tumors by selectively targeting and activating a specific subset of Vβ6 T cells. IPN60300 is a first-in-class antibody-drug conjugate (ADC) developed by Ipsen and Foreseen Biotechnology, designed to target solid tumors. The structural design of IPN60300 focuses on maximizing therapeutic index and selectivity, comprising three main components.
Market Sentiment and Share Price Momentum
The latest oncology data and recent conference activity come at a time when Ipsen’s share price has reached €157.7, with recent momentum reflected in a 90-day share price return of 32.97% and a 1-year total shareholder return of 48.68%. This indicates that sentiment has strengthened over both shorter and longer horizons.
With Ipsen trading at €157.7, a touch above the €151.94 analyst price target yet showing a 39% intrinsic discount estimate, you have to ask: is there still mispricing here, or is the market already baking in future growth?
With Ipsen’s fair value estimate at €151.94 and the last close at €157.7, the most followed narrative suggests the price is already slightly ahead of its fundamentals, putting the focus firmly on how the pipeline and margins evolve from here.
Looking Ahead: Pipeline Catalysts
Anticipated late-stage pipeline catalysts in 2025 to 2026 across all three therapeutic areas, including pivotal readouts and further regulatory submissions, improve visibility on new product revenue streams, reducing future earnings risk from maturing assets.
